Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.96 USD
+0.14 (7.69%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $1.98 +0.02 (1.02%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Esperion Therapeutics (ESPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.08 | $16.00 | $2.50 | 343.96% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Esperion Therapeutics comes to $8.08. The forecasts range from a low of $2.50 to a high of $16.00. The average price target represents an increase of 343.96% from the last closing price of $1.82.
Analyst Price Targets (6 )
Broker Rating
Esperion Therapeutics currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 57.14% and 14.29% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/24/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
6/28/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
6/28/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/2/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $8.08 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -0.14 |
ESPR FAQs
Esperion Therapeutics, Inc. (ESPR) currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Esperion Therapeutics, Inc. (ESPR) is $8.08. The current on short-term price targets is based on 5 reports.
The forecasts for Esperion Therapeutics, Inc. (ESPR) range from a low of $2.5 to a high of $16. The average price target represents a increase of $312.24 from the last closing price of $1.96.
The current UPSIDE for Esperion Therapeutics, Inc. (ESPR) is 312.24%
Based on short-term price targets offered by six analysts, the average price target for Esperion Therapeutics comes to $8.08. The forecasts range from a low of $2.50 to a high of $16.00. The average price target represents an increase of 343.96% from the last closing price of $1.82.